Detailed Narrative
Q1 FY26 Performance Overview
Glenmark Pharmaceuticals reported a consolidated revenue from operations of INR 32,644 million for Q1 FY26, marking a modest Y-o-Y growth of 0.6%. The India formulation business contributed INR 12,399 million, growing 3.7% Y-o-Y, while the Consumer Care segment saw a robust 20% Y-o-Y growth. North America revenues stood at INR 7,780 million (USD 91 million), showing an 8.9% Q-o-Q growth, despite a challenging environment. Europe and Emerging Markets experienced a Y-o-Y decline of 4% and a flat growth of 0.2% respectively.
India Business Strategy and Performance
The India business continued to outperform the overall industry in secondary sales, recording 15.1% growth in Q1 FY26 compared to the IPM's 8.5%. This growth was robust across cardiac, respiratory, and dermatology therapy areas. Management indicated that the reported growth was impacted by the discontinuation of some tail-end brands and underperformance in the diabetes segment. However, with new launches like Tislelizumab, Zanubrutinib, and Empagliflozin, and full supply of Liraglutide, the company expects reported growth to align with secondary sales from Q3 FY26 onwards, targeting a 10-15% CAGR over the next 3-5 years.
North America Business and Regulatory Updates
North America revenues grew 8.9% Q-o-Q to USD 91 million, driven by injectable product launches and partnered products. Glenmark plans to file 1 application in the next quarter and 5-6 for the full year. The company settled a multi-district antitrust litigation for USD 37.75 million, while denying all allegations. The Monroe facility, which received 5 FDA observations, has responded, and the company hopes to restart commercial manufacturing this year, pending FDA resolution.
Global Markets Performance and Outlook
Europe's revenue declined 4% Y-o-Y to INR 6,678 million, but management anticipates a return to double-digit growth from Q2 FY26 onwards. Emerging Markets saw flat Y-o-Y growth at INR 5,721 million, primarily due to lower seasonal demand in Latin America, but is expected to achieve double-digit growth on a constant currency basis for FY26. Key brands like RYALTRIS continue to perform well globally, with marketing applications in over 90 countries and commercialization in over 45 markets.
IGI Oncology Pipeline and AbbVie Partnership
IGI (Glenmark's innovation arm) presented promising Phase 1 results for ISB 2001 in relapsed/refractory multiple myeloma, showing a 79% overall response rate. The landmark partnership with AbbVie for ISB 2001 grants AbbVie global rights (excluding emerging markets) and validates IGI's platform technology. The upfront payment from AbbVie, expected to be booked in Q2 FY26, will cover IGI's expenditure for the next 3 years (estimated at $210-225 million) and is projected to make Glenmark cash positive on a consolidated basis.
Capital Allocation and Financial Guidance
Net debt at the end of Q1 FY26 stood at INR 1,500 crores, with gross debt at INR 3,200 crores. Capital expenditure for the quarter was INR 180 crores, with the full-year guidance remaining on track. R&D expenditure for Q1 was around 7% of revenue, with half related to IGI. Management guided for EBITDA margins to stabilize at 23%+ from Q3 FY26 onwards, driven by the strategic focus on high-margin branded products and a diversified geographical portfolio. Net working capital days are targeted to be maintained at 110-115 days.